BioAge Labs Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kristen Fortney
- Full Time Employees
- 61
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5885 Hollis Street Emeryville CA United States of America 94608
- IPO Date
- Sep 26, 2024
- CIK
- 0001709941
- Website
- bioagelabs.com
- Similar Companies
- Business
- BioAge Labs, Inc. (BIOA) is a clinical-stage biopharmaceutical company that develops therapies targeting the biology of human aging to treat metabolic diseases including obesity, cardiometabolic disorders, and neuroinflammation-driven conditions; its proprietary human-centric discovery platform analyzes multi-omics datasets from longevity cohorts to identify molecular targets and pathways underlying age-related decline. The company's lead product candidate is BGE-102 (azelaprag), an orally available, brain-penetrant NLRP3 inhibitor advancing toward Phase 1 trials in the second half of 2025 for obesity and related indications, complemented by a portfolio of structurally novel APJ receptor agonists such as oral small molecules and long-acting injectables designed to enhance weight loss, preserve muscle, and address insulin resistance in older adults, alongside preclinical programs focused on chronic inflammation and metabolic aging pathways. Founded in 2015 and headquartered in Richmond, California, BioAge operates globally with a focus on North American clinical development and serves pharmaceutical partners and patients with age-associated metabolic conditions. Recent developments include a multi-year research collaboration with Novartis announced in December 2024 to discover targets at the intersection of aging biology and exercise physiology, potentially worth up to $530 million in milestones; a strategic partnership with Lilly ExploR&D in January 2025 for therapeutic antibodies against novel metabolic aging targets; a June 2025 initiative with the HUNT Biobank in Norway to profile over 17,000 samples for drug discovery insights; advancements in its apelin pipeline through antibody partnerships and patent filings for oral APJ agonists; and an initial public offering in September 2024 that bolstered its cash position to fund operations into 2029.
Company News
BioAge Labs to Present at Upcoming Investor Conferences
214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
Why Is BioAge Labs Stock Sinking Friday?
BioAge Labs (NASDAQ:BIOA) Trading Up 5.5% – Should You Buy?
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BioAge Labs to Present at Upcoming Investor Conferences
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap, and More
BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile
BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know